|1.||Attention Deficit and Disruptive Behavior Disorders (Oppositional Defiant Disorder)
|2.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
|3.||Mental Disorders (Mental Disorder)
|4.||Anxiety Disorders (Anxiety Disorder)
|5.||Schizophrenia (Dementia Praecox)
|1.||Masi, Gabriele: 9 articles (10/2015 - 01/2006)|
|2.||Grant, Bridget F: 9 articles (07/2010 - 06/2005)|
|3.||Iacono, William G: 8 articles (10/2013 - 02/2003)|
|4.||Goldstein, Risë B: 8 articles (07/2010 - 09/2006)|
|5.||Milone, Annarita: 7 articles (10/2015 - 01/2006)|
|6.||Findling, Robert L: 7 articles (09/2014 - 01/2004)|
|7.||Stallings, Michael C: 7 articles (07/2014 - 02/2006)|
|8.||Heath, A C: 6 articles (12/2015 - 01/2000)|
|9.||Bucholz, K K: 6 articles (12/2015 - 01/2000)|
|10.||Faraone, Stephen V: 6 articles (05/2015 - 04/2002)|
|1.||Risperidone (Risperdal Consta)FDA LinkGeneric
04/01/2000 - "To examine whether risperidone is superior to placebo in the treatment of youths with conduct disorder. "
01/01/2011 - "The aim of this study is to obtain preliminary data about the efficacy and tolerability of risperidone treatment in otherwise typically developing preschool children with conduct disorder and severe behavioral problems. "
02/01/2008 - "The aim of this study was to investigate the effectiveness of risperidone and psychosocial treatment as compared to psychosocial treatment alone in reducing disruptive behavior in adolescents with persistent conduct disorder (CD). "
01/01/2003 - "Risperidone in children and adolescents with conduct disorder: a single-center, open-label study."
01/17/2014 - "Risperidone was most commonly prescribed for patients with hyperkinetic disorders and conduct disorders. "
04/01/1995 - "Lithium appears to be an effective treatment for some severely aggressive children with conduct disorder. "
11/01/1993 - "Lithium administration has been effective in treating severe aggression in children and adolescents with Conduct Disorder. "
07/01/2000 - "Lithium is a safe and effective short-term treatment for aggression in inpatients with conduct disorder, although its use is associated with adverse effects."
01/01/2009 - "Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study."
07/01/2000 - "A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder."
|3.||Valproic Acid (Valproate, Semisodium)FDA LinkGeneric
01/01/2006 - "This study examines the efficacy of a specific compound, divalproex sodium (DVPX), on the various levels of psychopathology, utilizing a previous study in which 71 youth with conduct disorder were enrolled in a randomized controlled 7-week clinical trial. "
10/01/2003 - "We aimed to test the efficacy of divalproex sodium for the treatment of conduct disorder. "
10/01/2011 - "To investigate response to Divalproex sodium (DVPX) with respect to Reactive/Affective/Defensive/Impulsive (RADI) and Proactive/Instrumental/Premeditated (PIP) aggression among adolescent males with conduct disorder (CD), using results from a randomized, double-blind, placebo-controlled trial. "
12/01/2005 - "Predictors of response to divalproex treatment for conduct disorder were identified, despite the small sample size in this study. "
10/01/2003 - "This preliminary study in a most difficult population suggests a role for divalproex sodium in the treatment of conduct disorder. "
|4.||quetiapine (Seroquel)FDA Link
04/01/2008 - "The aim of this study was to examine whether quetiapine is superior to placebo in the treatment of adolescents with conduct disorder. "
10/01/2013 - "The aim of this study was to assess the efficacy of quetiapine monotherapy in adolescents with BD comorbid with conduct disorder (CD). "
02/01/2007 - "The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD). "
02/01/2007 - "A 26-week open-label study of quetiapine in children with conduct disorder."
04/01/2008 - "This methodologically controlled pilot study provides data that quetiapine may have efficacy in the treatment of adolescents with conduct disorder. "
|5.||Methylphenidate (Ritalin)FDA LinkGeneric
03/02/2007 - "a) Girls have certain specific clinical manifestations within the three common symptoms; b) methylphenidate is equally effective in both sexes; c) only boys display other disorders such as negativism and conduct disorders; and d) the brains of males and females are quite similar, but symptoms are expressed differently depending on environments and levels."
05/01/2008 - "The authors conducted a prospective longitudinal study of 176 methylphenidate-treated Caucasian male children (ages 6 to 12) with ADHD but without conduct disorder. "
05/01/2005 - "Patients presenting comorbidities (ie conduct disorder, -anxiety, depression) as well as a history of previous treatment with methylphenidate were also eligible to participate. "
10/01/1991 - "Methylphenidate and hospitalized adolescents with conduct disorder: Dose effects on classroom behavior, academic performance, and impulsivity."
09/01/1990 - "Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report."
|6.||aripiprazole (Abilify)FDA Link
11/01/2011 - "Aripiprazole was an effective and relatively well-tolerated treatment for overall aggression in adolescent males with conduct disorder, in the view of both clinicians and parents. "
11/01/2011 - "Ten adolescent male patients diagnosed with conduct disorder received aripiprazole in doses of ≤20 mg/d in an open-label, intent-to-treat design to establish and characterize the efficacy of the drug in reducing aggressive behavior. "
07/01/2015 - "Aripiprazole in Children and Adolescents with Conduct Disorder: A Single-Center, Open-Label Study."
01/01/2012 - "Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study."
11/01/2011 - "An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder."
|7.||Clonidine (ST 155)FDA LinkGeneric
01/01/2000 - "These results suggest the safety and efficacy of clonidine alone or in combination with MPH for the treatment of ADHD and aggressive oppositional and conduct disorders."
06/01/1997 - "The usefulness of the antihypertensive drug clonidine in the treatment of pathologic aggression has not been assessed adequately, and only marginal benefits were observed with this drug in irritable autistic and conduct disorder children. "
12/01/1999 - "Meta-analysis using weighted variables revealed clonidine demonstrates a moderate effect size of 0.58 +/- 0.16 (95% confidence interval = 0.27-0.89) on symptoms of ADHD in children and adolescents with ADHD and ADHD comorbid with conduct disorder, developmental delay, and tic disorders. "
07/01/1994 - "Our findings suggest that clonidine may prove to be an alternative treatment of comorbid attention deficit hyperactivity disorder and conduct disorder."
07/01/1994 - "Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit."
08/01/1994 - "Although further study is required to confirm the therapeutic efficacy and to define the precise nature of iron deficiency in conduct disorder, the weight of the evidence suggests that correcting the nutrient deficit may be an essential step toward a refinement of therapeutic strategies. "
12/01/2010 - "The mean scores of conduct disorder, socialized aggression, and anxiety withdrawal of RBPCL were higher in thalassemic group while the mean scores of motor excess and attention problems score were higher in the iron deficiency group. "
08/01/1994 - "The presence of a borderline hemogram, hypermenorrhea and malnutrition should alert clinicians to the possibility of iron deficiency, and laboratory screening for hypoferremia should be considered when assessing conduct disorder."
|9.||Antidepressive Agents (Antidepressants)IBA
04/01/2010 - "History of physical and/or sexual abuse, exposure to antidepressants, and exposure to stimulants was significantly greater among offspring with versus without BP. There was significantly greater prevalence of attention-deficit/hyperactivity disorder (ADHD), anxiety disorders, oppositional defiant disorder/conduct disorder (ODD/CD), and exposure to stimulants and antidepressants among offspring with versus without BP. Variables significantly associated with BP among offspring in regression analyses were as follows: older offspring age, younger parent age at birth, offspring anxiety disorders and ODD/CD, and biological coparent with BP. History of anxiety and/or disruptive behavior disorders, as well as presence of bi-lineal parental BP, is associated with elevated risk of bipolar spectrum disorders among offspring. "
01/01/1997 - "Although fluoxetine might be more effective than placebo for treating adolescent depression without major comorbidity, little is known about the response of depressive symptoms to antidepressants in adolescents with comorbid conduct disorder (CD) and substance use disorders (SUD). "
02/01/2014 - "Risk factors obtained by regression analysis did not include methylphenidate but did include antidepressants, antipsychotics, and mixed medications, in combination with co-morbid mood, anxiety, personality, and conduct disorders, and older age at diagnosis. "
01/01/2006 - "Evidence suggests that antipsychotics, antidepressants, mood stabilisers, antiepileptic drugs, stimulants and adrenergic drugs can be well tolerated and effective therapeutic options for individuals with conduct disorder and comorbid psychiatric conditions. "
|10.||atomoxetine (Strattera)FDA LinkGeneric
12/01/2013 - "Atomoxetine also decreased the opposition defiance subscale scores of T-DSM-IV (both parent and teacher forms), whereas it was not found to make statistically significant difference in the conduct disorder subscale scores. "
06/01/2011 - "Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder."
09/01/2007 - "Preliminary data also support the potential efficacy of atomoxetine in managing patients with ADHD and comorbid conditions, such as tic disorders, oppositional-defiant and conduct disorders. "
07/01/2015 - "To compare the reduction of ADHD symptoms under atomoxetine in patients with and without comorbid oppositional defiant disorder (ODD) or conduct disorder (CD) using a computer-based continuous performance test (cb-CPT) combined with an infrared motion tracking (MT) device. "
06/01/2011 - "To evaluate the effect of atomoxetine on quality of life (QoL) and family burden in children and adolescents with attention deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant (ODD) or conduct disorder (CD). "
03/01/1999 - "Although the children with a conduct disorder also showed improvement after treatment, their CBCL scores remained high. "
01/01/2006 - "Inhalant use among adolescent males in treatment for substance and behavior problems may predict more severe conduct disorder symptoms after treatment."
10/01/1995 - "37 Mothers of children with conduct disorder who had received Parent Management Training (PMT) were interviewed using the Adult Attachment Interview, 13-43 months after treatment. "
|2.||Drug Therapy (Chemotherapy)
07/01/2012 - "There are few well controlled studies of the pharmacotherapy of conduct disorder in children and adolescents. "
12/01/2014 - "In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. "
07/01/2012 - "[Pharmacotherapy for conduct disorder in children and adolescents]."
10/01/2006 - "Her behavioural changes had manifested as conduct disorder and were treated with pharmacotherapy as well as behavioural therapy."
02/01/2004 - "Effectiveness of an outpatient treatment of children and adolescents with conduct disorders can be increased by training of parents, home treatment or pharmacotherapy."
08/01/1947 - "Prefrontal lobotomy for severe conduct disorder."
03/02/1946 - "Prefrontal leucotomy in treatment of post-encephalitic conduct disorder."
|4.||Ambulatory Care (Outpatient Care)
02/01/2005 - "To describe the documented adherence to quality indicators for the outpatient care of attention-deficit/hyperactivity disorder, conduct disorder, and major depression for children in public mental health clinics and to explore how adherence varies by child and clinic characteristics. "
04/01/1995 - "Factors that predict psychiatric hospitalization rather than outpatient care are (1) public or private insurance coverage versus no insurance; (2) previous hospitalization; (3) psychiatric diagnosis of affective or psychotic disorders versus conduct disorders, adjustment disorders, drug and alcohol abuse, and other disorders; and (4) age, with adolescents more likely to be hospitalized than children. "